<DOC>
	<DOC>NCT00499850</DOC>
	<brief_summary>A Phase I,open label study to assess the safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal adenocarcinoma.</brief_summary>
	<brief_title>Phase I FOLFOX Combination</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1. Histologically confirmed locally advanced, recurrent or metastatic colorectal adenocarcinoma (Stage IV) 2. WHO performance status 01 3. one or more measurable lesions min 10mm by spiral CT or min 20mm by conventional techniques 1. Brain metastasis or spinal cord compression unless irradiated at least 4 weeks before entry and stable 2. last dose of prior chemotherapy discontinued at least 4 weeks before start study treatment 3. prior unanticipated severe reaction to oxaliplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ZD6474</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>colorectal</keyword>
	<keyword>adenocarcinoma</keyword>
</DOC>